生物制剂治疗对有恶性肿瘤病史的类风湿关节炎患者新发或复发癌症风险的荟萃分析
TNFi(相对风险=0.95,95%CI=0.83,1.09)与利妥昔单抗(相对风险=0.89,95%CI=0.52,1.53)均未见癌症风险升高,按癌种、既往癌诊断至TNFi启动间隔及TNFi暴露时长分层结果相似。
要点
- 有既往癌症史的RA患者使用生物制剂,总体新发或复发癌症风险较csDMARDs未见升高。
- TNFi相对风险=0.95(95%CI=0.83,1.09),利妥昔单抗相对风险=0.89(95%CI=0.52,1.53)。
- 癌种、既往癌至TNFi启动间隔及TNFi暴露时长分层分析结果与主分析相似。
核心结论
- 与csDMARDs相比,有既往癌症史的RA患者接受生物制剂未增加总体或部分特定亚型癌症的发生风险。
- 仍需更多研究探讨单个癌种的癌症发生风险,以及明确癌症诊断后或癌症治疗结束后启动生物治疗的最佳时机。
研究设计与样本
- 系统检索PubMed、EMBASE、Cochrane Library及会议论文集,纳入报告有既往恶性肿瘤史的RA患者使用生物制剂与csDMARDs后癌症发生率或复发率的观察性研究。
主要发现
- 每1000患者年新发和复发癌症粗发生率:TNFi为34.4,利妥昔单抗为32.3,阿那白滞素为32.3,csDMARDs为31.8。
- 定量荟萃分析中,生物制剂与csDMARDs相比新发或复发癌症风险未升高:TNFi相对风险=0.95,95%CI=0.83,1.09;利妥昔单抗相对风险=0.89,95%CI=0.52,1.53。
- 按癌种分层、按TNFi启动与既往癌症诊断间隔分层、按TNFi暴露时长分层的二次分析均得到相似结果。
关键数值与推荐
- TNFi相对风险=0.95,95%CI=0.83,1.09(有既往癌症史的RA患者,与csDMARDs比较)。
- 利妥昔单抗相对风险=0.89,95%CI=0.52,1.53(同上人群与对照)。
- 每1000患者年新发和复发癌症粗发生率:TNFi 34.4、利妥昔单抗32.3、阿那白滞素32.3、csDMARDs 31.8。
临床怎么用
- 对于有既往恶性肿瘤史的RA患者,在选择TNFi或利妥昔单抗时,本荟萃分析未显示其较csDMARDs增加总体新发或复发癌症风险,可作为医患沟通与决策的参考。
- 由于单个癌种风险及最佳生物制剂启动时机尚不明确,临床仍需结合既往癌种、治疗结束时间与个体情况个体化评估与随访。
局限性
- 纳入研究均为观察性研究,可能存在混杂与偏倚。
- 阿那白滞素相关研究仅1项,利妥昔单抗研究3项,部分生物制剂证据量有限。
- 单个癌种风险及癌症诊断后或治疗结束后启动生物治疗的最佳时机尚需更多研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To explore the risk of new and recurrent cancer in adult RA patients with prior malignancy and subsequently exposed to biologic therapies. METHODS: Separate searches were performed of PubMed, EMBASE and Cochrane Library and conference proceedings for observational studies reporting cancer incidence or recurrence in patients with RA and prior malignancy treated with biologics and conventional synthetic DMARDs (csDMARDs). Mantel-Haenszel fixed-effects method was conducted to calculate relative risk and 95% CI. RESULTS: A total of 12 studies involving 13 598 patients and 32 473 patient-years of follow-up were included (10, 3 and 1 studies for TNF inhibitors [TNFi], rituximab and anakinra, respectively). The crude incidence of new and recurrent cancer per 1000 patient-years were 34.4 for TNFi, 32.3 for rituximab, 32.3 for anakinra and 31.8 for csDMARDs. In the quantitative meta-analysis, biologics were not associated with an increased risk of new or recurrent cancer compared with csDMARDs in patients with RA and prior cancer (TNFi: relative risk = 0.95, 95% CI = 0.83, 1.09; rituximab: relative risk = 0.89, 95% CI = 0.52, 1.53). Secondary analyses of stratification of cancer types, the interval between initiation of TNFi and prior cancer diagnosis, and duration of TNFi exposure, found similar results. CONCLUSION: Compared with csDMARDs, there is no increased risk of developing cancer overall or some specific subtypes in RA patients with a prior cancer receiving biologics. More investigations are warranted to explore the risk of cancer development in individual cancer as well as to determine optimal time to initiate biologic therapy after the diagnosis of cancer or completion of cancer treatment.
引用
- Xie W, Xiao S, Huang Y, et al. A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy. Rheumatology (Oxford). 2020. PMID: 31620795. doi:10.1093/rheumatology/kez475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。